Divine Aleru, Microbiome Signatures Research Coordinator

Copper’s dual role as both an antimicrobial and essential micronutrient plays a significant part in the host-pathogen interaction, with pathogens evolving resistance mechanisms while hosts leverage copper to combat infections. This study offers insights into how copper impacts infection biology, potentially informing new therapeutic strategies.

This study links the Cu/Zn ratio with markers of disease activity in IBD, suggesting it as a potential biomarker for disease monitoring. It emphasizes the role of zinc and copper deficiencies in IBD progression.

The study reveals a higher prevalence of zinc deficiency in Crohn’s disease patients compared to healthy controls. While serum zinc levels did not differ significantly between groups, the increased deficiency rate in CD highlights the need for zinc monitoring and potential supplementation in these patients.

This review explores siderophore-mediated iron acquisition in the gut, its role in bacterial growth, and its impact on microbial community dynamics and host immunity, with implications for IBD, infections, and colorectal cancer.

This study highlights the high prevalence of iron deficiency anemia (IDA) in Crohn’s disease patients and its association with worse hospitalization outcomes, including longer stays, higher costs, and more readmissions. The findings stress the need for early IDA screening and management in this population.

This study reveals altered fecal bile acid composition in IBD patients, especially UC, suggesting the potential of bile acids as biomarkers for disease severity and differentiation between UC and CD.

This study links gut microbiota dysbiosis with bile acid composition changes in Crohn’s disease. The altered microbial and bile acid profiles may play a significant role in disease progression, offering potential therapeutic avenues.

This review discusses succinate’s role in IBD pathogenesis, focusing on its dual role in inflammation and tissue repair. The review underscores the importance of microbiota-driven succinate regulation and explores potential therapeutic strategies targeting succinate metabolism in IBD.

This narrative review explores succinate’s dual immunoregulatory roles in IBD, examining how its concentration affects inflammation and tissue repair. The study discusses potential therapeutic strategies targeting succinate metabolism and its signaling pathways.

This review investigates how gut microbiota dysbiosis impacts metabolic functions and immune responses in inflammatory bowel disease (IBD), highlighting key microbial changes and therapeutic potential through microbiome manipulation.

This study reveals the significant role of gut microbiome and metabolome signatures in predicting infliximab response in Crohn’s Disease, suggesting that microbiome-based biomarkers could guide personalized treatment strategies.

This study highlights the complex relationship between the gut microbiota, the immune system, and intestinal health. It emphasizes how disruptions to this balance can lead to chronic diseases like inflammatory bowel disease.

This review examines the environmental and genetic factors influencing Crohn’s disease, offering insight into how these factors contribute to disease onset, progression, and management. The study highlights the increasing incidence in developing countries and the role of diet, smoking, and infections.

This study systematically reviews the use of AI-assisted capsule endoscopy for detecting lesions in Crohn’s disease. AI showed high diagnostic accuracy with a sensitivity of 94% and specificity of 97%, highlighting its potential to improve the diagnostic process, though more research is needed for validation.

This review examines how migration and environmental risk factors influence the onset and course of inflammatory bowel diseases (IBD), with a focus on migrant populations transitioning from low-incidence to high-incidence regions. It emphasizes the need for further studies on generational changes and environmental triggers of IBD.

This review explores environmental factors such as smoking, diet, and air pollution that influence the onset and progression of Crohn’s disease. It highlights the importance of smoking cessation and dietary adjustments in managing the disease.

This review investigates the ongoing debate over the potential role of Mycobacterium avium subspecies paratuberculosis in Crohn’s disease. Despite frequent detection in patients, MAP’s causative role remains unproven, with studies showing inconsistent results, particularly regarding treatment efficacy.

The study examines the debate surrounding Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn’s disease, with conflicting data on its role as a causative factor. Anti-MAP therapies show mixed results, highlighting the need for further investigation into MAP’s involvement in CD pathogenesis.

This review examines how microbial dysbiosis in the gut contributes to systemic autoimmune diseases like type 1 diabetes, MS, RA, and SLE. It emphasizes microbial influences on immune responses and suggests potential microbiome-based therapies.

This review discusses the role of gut microbiota dysbiosis in IBD, its interaction with intestinal barriers, and the potential of microbiota-targeted therapies like antibiotics, probiotics, and FMT in treating IBD.

This review focuses on the genetic and epigenetic factors that contribute to Inflammatory Bowel Disease (IBD), highlighting key genes and microbiome interactions, and their role in disease pathogenesis and treatment response.

This review explores immunomodulatory therapies for IBD, focusing on their impact on the gut-brain axis. It evaluates conventional and emerging treatments like biologics, FMT, and probiotics, emphasizing their role in improving IBD outcomes and addressing neuropsychiatric symptoms.

The review examines the relationship between gut microbiota, diet, and extrinsic stressors in promoting intestinal inflammation, with implications for managing IBD. It emphasizes the potential benefits of dietary changes and probiotics in restoring gut health and mitigating inflammation.

This review explores the genetic complexities of NOD2 in Crohn’s disease, emphasizing its role in the stricturing phenotype and the need for deeper research into rare variants and their functional impacts.

This review highlights the genetic and environmental factors influencing Crohn’s disease, including the role of NOD2 mutations, smoking, diet, and vitamin D deficiency. It underscores the need for personalized treatment strategies to manage this complex disease.

This review discusses the pathogenesis of osteoporosis in Crohn’s disease, focusing on the role of cytokines, glucocorticoids, and malnutrition. It emphasizes the importance of early detection and treatment strategies to prevent fractures and improve patient outcomes.

This review discusses nephrolithiasis in Crohn’s disease patients, highlighting the increased risk, pathophysiology, and preventative measures. It emphasizes dietary interventions and fluid intake to reduce the formation of kidney stones.

This review explores the link between IBD and thromboembolic events, highlighting the increased risks, particularly in patients with active disease, corticosteroid treatment, and post-surgery. It emphasizes the need for thromboprophylaxis and further research on the pathophysiology of these complications.

This study explores the long-term risk of developing IBD in AIH patients, identifying smoking as a significant risk factor and showing that while IBD increases cirrhosis prevalence, it does not worsen liver-related complications in AIH patients.

This review explores the relationship between pyoderma gangrenosum and inflammatory bowel disease, focusing on epidemiology, clinical features, and treatment approaches. It emphasizes the need for more research to standardize diagnosis and treatment protocols, especially in light of the growing use of biologics.

This review discusses the extraintestinal manifestations of IBD, focusing on the pathophysiology, prevalence, and associations with treatment. It emphasizes the role of immune system dysfunction, genetics, and microbiome in triggering these manifestations, with implications for clinical management.

This review explores ocular manifestations in IBD, including episcleritis, uveitis, and scleritis, discussing their pathophysiology, epidemiology, and management, with an emphasis on the role of IBD treatments and the impact of the microbiome.

This review updates the current understanding of PSC-IBD, discussing its unique clinical features, the increased risk of malignancies, and the challenges in managing this comorbidity.

This systematic review and meta-analysis examines the incidence and risk factors for paradoxical psoriasis or psoriasiform lesions in IBD patients treated with anti-TNF therapy, providing crucial insights into the dermatological side effects of these commonly prescribed medications.

This study finds that psoriasis is associated with an increased risk of developing inflammatory bowel disease, particularly ulcerative colitis, emphasizing the importance of early gastrointestinal monitoring in psoriasis patients.

This review examines the genetic, immune, and microbiological links between psoriasis and inflammatory bowel disease, focusing on shared pathophysiological mechanisms and treatment strategies.

This review discusses the pathogenesis of ankylosing spondylitis, highlighting the role of Type 17 immune responses, gut microbiome dysbiosis, and metabolic factors in disease development. It also explores therapeutic advancements targeting these pathways.

This article investigates the relationship between ankylosing spondylitis, Crohn’s disease, Klebsiella pneumoniae, and starch consumption, suggesting that high starch intake may trigger the growth of Klebsiella and exacerbate disease symptoms, with potential therapeutic implications for dietary management.

This study provides a comprehensive meta-analysis on the prevalence and bidirectional association between inflammatory bowel disease (IBD) and autoimmune liver disease (AILD), shedding light on the significant overlap between these conditions and their shared pathophysiological mechanisms.

This paper explores the nutritional status of IBD patients, highlighting common nutrient deficiencies, the importance of early screening, and the role of therapies like infliximab in improving nutritional outcomes.

This review explores the pathophysiology, prevalence, and treatment strategies for extraintestinal manifestations (EIMs) in Crohn’s disease and ulcerative colitis, emphasizing the role of immune responses, microbiome alterations, and biologic therapies in managing these systemic conditions.

This study examines the clinical features, risk factors, and treatment outcomes of intra-abdominal abscesses (IA) and intestinal free-wall perforations (IP) in Korean patients with Crohn’s disease, highlighting the role of intestinal stricture and disease behavior in complication development.

This review explores the pathophysiology, risk factors, and management of intestinal strictures in Crohn’s Disease, emphasizing genetic, environmental, and imaging factors, as well as current therapeutic approaches.

This review explores environmental risk factors for Crohn’s disease and ulcerative colitis, highlighting modifiable exposures such as smoking, diet, and early-life antibiotic use, and their impact on disease prevention.

This review explores the role of epithelial barrier dysfunction and microbial dysbiosis in the pathogenesis of Crohn’s disease, highlighting the impact of genetic, environmental, and microbiota factors on disease progression and the potential for therapeutic strategies to restore barrier integrity and balance microbial communities.

This review focuses on the complex pathogenesis of Crohn’s Disease, exploring the roles of microbiome dysbiosis, immune system dysregulation, and environmental factors in disease progression, while highlighting novel therapeutic and diagnostic strategies

This review explores the evolving role of microbiome-targeted therapies in Crohn’s disease, focusing on microbial dysbiosis and its implications for disease progression and treatment.

The study examines the role of microbiome in IBD, highlighting its potential in diagnosing, predicting disease progression, and personalizing treatments.

This study shows that Escherichia coli Nissle exerts strong dose dependent amebicidal activity against Entamoeba histolytica through oxidative stress and structural damage, highlighting its therapeutic potential.

Escherichia coli Nissle 1917 inhibited Candida albicans growth, reduced virulence traits and protected intestinal cells, showing strong preventive potential through contact based and soluble antifungal mechanisms.

This study shows that Klebsiella pneumoniae L fucose metabolism enhances gut colonization, strengthens biofilm and adherence traits, and increases virulence signalling, identifying a functional metabolic signature relevant to microbiome based clinical risk.

This study shows that the immuno modulatory effect of Escherichia coli Nissle 1917 primes polarized colonic cells, reduces Campylobacter jejuni adhesion and survival, and rebalances NF kappa B, MAPK and Akt signaling to limit inflammation and epithelial injury.

This study shows how Escherichia coli Nissle 1917 inhibitory mechanisms act through adhesion and suppression of EPEC virulence, defining a strong microbiome signature of pathogen interference.

This study shows that Escherichia coli Nissle 1917 microcin MccM is the key factor driving EcN’s inhibition of Salmonella, improving pathogen suppression, reducing cell invasion, and lowering inflammatory cytokine responses.

This study shows that DegP secretion drives probiotic Escherichia coli DegP biofilm inhibition by repressing pathogenic biofilms through a targeted extracellular mechanism that shapes microbial competition.

This study shows how F1C fimbriae in Escherichia coli Nissle 1917 drive biofilm formation, epithelial adhesion, and intestinal persistence, defining a functional microbiome signature for stable colonization.

This review explains how adhesive threads of extraintestinal pathogenic Escherichia coli shape gut colonization, tissue tropism and invasive disease and shows how detailed adhesin profiles can inform microbiome based risk assessment and vaccine design.

E. coli Nissle 1917 demonstrates significant antibiofilm activity against P. aeruginosa, inhibiting biofilm formation and dispersing mature biofilms. Its CFS also downregulates key virulence factors and offers protection in a Galleria mellonella model.

This review shows how Salmonella reshapes the gut environment and engages in Salmonella gut infection antagonistic interbacterial interactions with commensals, and it explains how bacteriocins and type six secretion systems shape microbiome signatures and infection risk.

his review shows how siderophore microcins in Escherichia coli support competitive gut colonization, connect the fecal reservoir with urinary tract infection, and define functional microbiome signatures that combine B2 background with microcin, salmochelin and colibactin islands.

This review explains intestinal effect of Escherichia coli Nissle 1917 and its vesicles on the gut barrier, dysbiosis and mucosal immunity, and it links these microbial actions to clinical outcomes in inflammatory bowel disease and acute diarrhoea.

Escherichia coli Nissle 1917 (EcN) is a highly regarded probiotic strain with significant clinical value due to its ability to outcompete a wide range of pathogenic microorganisms in the gastrointestinal tract. Through the formation of robust biofilms on intestinal epithelial surfaces, EcN effectively blocks the adhesion and colonization of pathogens such as Salmonella, Shigella, and Klebsiella pneumoniae.

Oral delivery of a glypican-1–flagellin fusion by engineered EcN triggered systemic IgG and regulatory IL-10 in mice, confirming a safe probiotic cancer-vaccine chassis but indicating the need for stronger cellular adjuvanticity for PDAC.

What was studied?Engineered Escherichia coli Nissle 1917 Pseudomonas aeruginosa control was tested as a live targeted therapy for gut infection. The authors rebuilt the earlier “sense-and-kill” circuit in a clinically used EcN background. The circuit sensed the P. aeruginosa quorum signal 3OC12-HSL. It then triggered lysis and release of pyocin S5, an antipseudomonal bacteriocin. It […]

Engineered EcN for phenylketonuria was upgraded to SYNB1934 using biosensor-enabled PAL evolution, doubling gut phenylalanine conversion and keeping biocontainment, supporting development of an oral strain for diet-refractory PKU.

Engineered Escherichia coli Nissle 1917 for hyperammonemia (SYNB1020) safely consumed gut ammonia, improved survival in mice, and showed dose-linked metabolic activity and clearance in healthy adults, supporting clinical development for urea cycle and liver-related hyperammonemia.

Engineering Escherichia coli Nissle 1917 therapeutics enables targeted antimicrobial, mucosal, metabolic, and anticancer actions but requires parallel engineering for biosafety and colibactin control.

Escherichia coli Nissle 1917, a probiotic strain, offers significant health benefits, but its genotoxic potential due to colibactin production raises safety concerns, particularly in relation to colorectal cancer. The review underscores the need for further research on the balance between benefits and risks.

Escherichia coli Nissle 1917 reduces the incidence of acute respiratory infections in late preterm newborns during the first month of life, with no adverse effects, highlighting its potential as a prophylactic intervention in this vulnerable population.

This study demonstrates that engineered E. coli Nissle 1917 can selectively colonize colorectal adenomas and reduce tumor burden in mice. The probiotic also shows promise for non-invasive detection and treatment of CRC in humans, suggesting a novel therapeutic and diagnostic platform.

Escherichia coli Nissle 1917 (EcN) shows promise as a tumour-targeting probiotic bacterium for cancer treatment and detection. This review investigates its tumour-homing abilities and outlines future research directions to optimize its use in clinical oncology.

This review analyzes the advancements in preventing urinary catheter-related infections (CAUTIs) through scientific publications and patents, highlighting innovations like antimicrobial-coated catheters and biofilm-resistant materials, with implications for clinical practice and healthcare systems.

Probiotic Escherichia coli Nissle 1917 iron competition reduced Salmonella in inflamed murine gut by using lipocalin-2–resistant siderophores and by dampening mucosal inflammation, showing a nutritional immunity route for probiotic therapy.

Escherichia coli Nissle 1917 acute diarrhoea therapy in infants and toddlers shortened illness from 4.8 to 2.5 days, raised response to 94.5%, and was as safe as placebo.

Escherichia coli Nissle 1917 improved IBS modestly overall but clearly in postinfectious or postantibiotic IBS, was as safe as placebo, and fits a dysbiosis-linked microbiome signature that needs 10–12 weeks of therapy to show.

Escherichia coli Nissle 1917 (EcN) significantly enhances protection against human rotavirus in gnotobiotic pigs by modulating plasmacytoid dendritic cells and NK cell responses, suggesting its potential as an effective probiotic treatment for viral gastroenteritis.

Escherichia coli Nissle 1917 (EcN) is a safe and effective probiotic for maintaining remission in ulcerative colitis patients, with clinical trial evidence showing equivalence to mesalazine in relapse prevention. Its mechanisms include immune modulation, antimicrobial activity, and gut barrier reinforcement.

Escherichia coli Nissle 1917 (EcN) interferes with the invasion of human intestinal epithelial cells by various pathogens through a secreted component, not by microcins or physical contact, suggesting its potential as a therapeutic probiotic to prevent gastrointestinal infections.

This study uncovers the dual role of Escherichia coli Nissle 1917, where its beneficial antibacterial activity is linked to the ClbP protein, while its genotoxic effects are dependent on colibactin. Engineering strains that decouple these activities could lead to safer probiotic therapies.

The study explores how Escherichia coli Nissle 1917’s microcins mediate competition in the inflamed gut, showing potential for therapeutic use in enterobacterial infections and colitis management.

E. coli Nissle uses yersiniabactin to bind zinc, overcome calprotectin, and colonize the inflamed gut, defining a metal-driven microbiome signature linked to Enterobacteriaceae dominance in colitis, with clear dependence on inflammation and pH.

Probiotic-e-coli-nissle-1917 shows benefit in ulcerative colitis, infant diarrhea, and innate immune priming, with transient engraftment and microcin-based pathogen suppression, but no effect in Crohn’s disease. Safety is strong, though neonatal products require caution.

E. coli Nissle 1917 is a non-pathogenic probiotic strain that inhibits pathogenic bacteria, reduces inflammation, and strengthens intestinal barrier function, with proven clinical efficacy in treating gastrointestinal diseases.

Escherichia coli Nissle 1917 (EcN) is a rare, non-pathogenic strain of E. coli discovered during World War I from a soldier who did not get dysentery while others did. Unlike harmful E. coli, EcN acts as a probiotic: it settles in the gut, competes with bad bacteria for food and space, produces natural antimicrobials, and even helps strengthen the gut barrier.

This study evaluates the inhibitory effects of Escherichia coli Nissle 1917 (EcN) on Clostridium perfringens type A, focusing on growth inhibition, toxin production, biofilm formation, and inflammatory cytokine responses in vitro.

Escherichia coli Nissle 1917 (EcN), a probiotic with a rich history, is now being engineered for therapeutic uses beyond gastrointestinal health, including metabolic disease treatment and immune modulation. Its potential in microbiome research and live vaccine development is also being explored.

The study discusses dietary strategies to counteract the toxicity of cadmium and lead exposure, emphasizing the role of essential metals, vitamins, probiotics, and edible plants. These strategies offer a safer, more accessible alternative to traditional chelation therapy.

The study emphasizes the potential benefits of zinc and multi-mineral supplementation in reducing cadmium toxicity. It links cadmium exposure to various health issues and suggests supplementation as a strategy to mitigate its harmful effects.

The review examines how cadmium exposure affects gut microbiota, leading to dysbiosis, increased gut permeability, and systemic inflammation. It also explores the potential of probiotics to mitigate cadmium-induced toxicity, suggesting new therapeutic strategies.

This study shows that cadmium exposure disrupts gut function in zebrafish, affecting villi morphology, goblet cell mucus production, and glycoprotein distribution. These changes may impair gut defense and highlight the environmental risks of cadmium contamination.

This study highlights the use of cadmium levels in saliva and urine as indicators of smoking addiction. It shows that cadmium concentrations correlate with tobacco use, offering a non-invasive method for assessing exposure in smokers and second-hand smokers.

The review shows that urinary cadmium biomarker long-term exposure provides a stable signal of cumulative dose. Smoking, age, sex, iron status, and kidney function shape values. Proper dilution adjustment and stratification improve validity for clinical and microbiome research.

This study examines how the combination of cadmium and iron oxide nanoparticles enhances the conjugative transfer of antibiotic resistance genes in microbial communities. It emphasizes the risk of accelerated antibiotic resistance spread, especially in human pathogens, under environmental pollution.

The study explores how cadmium and copper contamination in rhizosphere soil affects the distribution of antibiotic resistance genes. It shows that these metals contribute to the spread of resistance genes through co-selection, with significant implications for environmental and public health.

The review examines the sources, accumulation, and health effects of cadmium, emphasizing its long-term toxicity, particularly its role in lung, kidney, bone, and neurological diseases. It underscores the need for continued monitoring and preventive measures for populations at risk.

This study highlights the protective effects of Lactobacillus plantarum CCFM8610 probiotics against cadmium toxicity by preserving intestinal barrier function and reducing oxidative stress, offering a potential therapeutic strategy for preventing heavy metal absorption.

The study examines how cadmium exposure alters the microbiota in rats, causing microbial translocation and metabolic shifts. The findings highlight potential biomarkers for assessing cadmium toxicity.

This study reveals how low-dose cadmium exposure disrupts gut microbiota, increasing intestinal permeability and liver injury in mice. The findings emphasize the role of microbiota in modulating toxin absorption and liver function.

This study highlights the significant impact of environmental pollutants on the gut microbiome, selecting for microbial functions that degrade xenobiotics and potentially promoting antibiotic resistance. Understanding these changes can provide insights into the role of the microbiome in detoxifying pollutants and influencing human health.

This review discusses the strategies for translating microbiome-based therapies into clinical practice for FGIDs, particularly IBS. It highlights the need for a systems approach integrating multi-omics data and patient stratification.